ARTVIGIL 150

What is ARTVIGIL 150?

ARTVIGIL 150 is a modern drug from the group of nootropics and psychostimulants, used for the correction of conditions associated with excessive daytime sleepiness and cognitive impairment. The main active substance of the drug is armodafinil — an enantiomerically pure form of modafinil, which provides a longer and more stable therapeutic effect compared to its predecessors. The drug is produced in the form of tablets for oral use, each containing 150 mg of the active component, allowing precise dosing of the medication according to individual patient needs. The manufacturer of ARTVIGIL 150 is the pharmaceutical company Signature, which specializes in producing high-quality generics and innovative drugs for the treatment of neurological disorders. The pharmacological group of the drug includes psychoanaleptics and agents that enhance mental performance, making it useful in various medical fields — from somnology to psychiatry.

The mechanism of action of armodafinil fundamentally differs from classic stimulants such as amphetamine or methylphenidate, as it does not cause pronounced euphoria and has a significantly lower potential for abuse. The active substance selectively acts on specific regions of the hypothalamus, increasing levels of dopamine, norepinephrine, and histamine in the synaptic cleft, leading to a sustained state of wakefulness without excessive psychomotor activation. This approach allows patients to maintain mental clarity, concentration, and the ability to perform productively throughout the day. ARTVIGIL 150 does not disrupt the natural architecture of nighttime sleep provided proper dosing schedules are followed, which favorably distinguishes it from other wakefulness-promoting agents. The drug is well absorbed in the gastrointestinal tract, reaching peak plasma concentration approximately two hours after administration, and its half-life is about 15 hours, providing a long-lasting effect throughout the day.

ARTVIGIL 150 belongs to the category of prescription drugs, so its use must occur exclusively as prescribed by a physician following a thorough examination and accurate diagnosis. Self-medication with this product is unacceptable, as an incorrect dosage regimen can lead to adverse reactions affecting the cardiovascular and nervous systems. Specialists note that the drug demonstrates high efficacy in patients with narcolepsy, obstructive sleep apnea, and shift work sleep disorders. Thanks to modern manufacturing technologies, Signature guarantees consistent quality for every batch of the drug, supported by international certificates of conformity. Clinical studies show that armodafinil at a dose of 150 mg provides an optimal balance between therapeutic efficacy and safety profile for most patients.

Why is ARTVIGIL 150 prescribed?

The main indications for the use of ARTVIGIL 150 are conditions accompanied by pathological daytime sleepiness, which significantly reduces the patient's quality of life and working capacity. Most often, the drug is prescribed for narcolepsy — a chronic neurological disorder characterized by sudden attacks of irresistible sleep during the day, cataplexy, and nighttime sleep disturbances. In such patients, armodafinil helps maintain a stable level of wakefulness, reduces the frequency of sudden falling asleep episodes, and allows for a more active lifestyle. Clinical observations show that regular use of the drug significantly improves attention metrics, reaction speed, and overall cognitive performance in narcolepsy patients.

The second important area of application for ARTVIGIL 150 is obstructive sleep apnea syndrome, in which patients suffer from chronic fatigue and sleepiness due to repeated breathing cessations during sleep. The drug does not treat the apnea itself, but effectively eliminates its consequences in the form of daytime hypersomnia, especially when combined with primary treatments such as CPAP therapy. Doctors also prescribe this agent for shift work sleep disorder, when professional activity requires night shift alertness or frequent travel across multiple time zones. In these cases, armodafinil helps adapt the body's biological rhythms to non-standard conditions, reducing feelings of exhaustion and improving the ability to concentrate during work shifts.

It is also worth highlighting the use of ARTVIGIL 150 in the comprehensive therapy of cognitive impairments of various origins, particularly in adult attention deficit disorder, effects of traumatic brain injuries, and post-neuroinfection conditions. The drug improves executive functions, working memory, and planning ability, making it useful for patients requiring restoration of mental capacity. In some cases, doctors may recommend armodafinil for severe asthenia accompanying chronic diseases; however, such use requires special caution and careful monitoring of the patient's condition. It is important to understand that the drug is not a performance enhancer for healthy individuals, and its use without medical indications can be dangerous to health.

Composition and active components of ARTVIGIL 150

Each ARTVIGIL 150 tablet contains 150 mg of armodafinil as the primary active substance, which is the R-enantiomer of modafinil and provides a more pronounced and prolonged effect compared to the racemic mixture. Armodafinil selectively binds to the dopamine transporter in the brain, blocking dopamine reuptake and increasing its concentration in the synaptic cleft. This mechanism activates the ascending pathways of the reticular formation responsible for maintaining a state of wakefulness, resulting in a rapid and sustained awakening effect. Unlike traditional psychostimulants, armodafinil does not cause significant dopamine release from vesicles, making its action more physiological and less toxic to neurons.

The inactive ingredients of the drug include lactose monohydrate, which acts as a filler and provides the necessary tablet mass, and microcrystalline cellulose as a binding agent that provides strength and shape stability to the tablet. The formulation also includes croscarmellose sodium, which promotes rapid tablet disintegration in the gastrointestinal tract and improves the bioavailability of the active component, and magnesium stearate as an anti-frictional agent to prevent sticking of components during manufacturing. All excipients are standard for the pharmaceutical industry, have undergone necessary toxicological testing, and do not affect the therapeutic activity of the drug. The composition of ARTVIGIL 150 is designed to ensure optimal release of armodafinil and its stable absorption regardless of food intake.

The pharmacokinetic properties of armodafinil are characterized by high bioavailability, which is independent of food intake, although high-fat food may slightly delay the rate of absorption. Following oral administration, the drug is rapidly distributed into body tissues, crosses the blood-brain barrier, and reaches therapeutic concentrations in the central nervous system. Metabolism of armodafinil occurs primarily in the liver with the participation of cytochrome P450 enzymes, particularly the CYP3A4 isoenzyme, which must be taken into account during concomitant use of other drugs. Elimination of the drug is carried out by the kidneys in the form of inactive metabolites, with a half-life of about 15 hours, allowing for once-daily dosing. Such pharmacokinetics provide a stable concentration of the active substance throughout the patient's active period.

ARTVIGIL 150 Dosage

The standard recommended dose of ARTVIGIL 150 for adult patients is 150 mg once daily, usually taken in the morning or one hour before the start of a work shift for individuals with irregular work schedules. This dosage regimen provides optimal therapeutic effect throughout the day without the need for additional medication. In patients with narcolepsy and obstructive sleep apnea syndrome, doctors usually recommend taking the drug in the morning to avoid night sleep disturbances. For night shift workers, ARTVIGIL 150 is taken approximately one hour before starting work, maintaining high levels of wakefulness and concentration throughout the shift.

The duration of treatment is determined individually depending on the diagnosis, severity of symptoms, and the patient's response to therapy. In chronic conditions such as narcolepsy, the drug may be used long-term, but regular medical supervision is required to evaluate efficacy and promptly identify potential side effects. In patients with severe hepatic impairment, the dosage may be reduced to 100 mg per day, requiring appropriate dose formulations or adjustment of the administration schedule. For elderly patients, special dose adjustment is usually not required; however, it is recommended to start treatment with the lowest effective dose and closely monitor cardiovascular status.

It is important to emphasize that exceeding the recommended dose of ARTVIGIL 150 does not lead to increased therapeutic effect, but significantly increases the risk of adverse reactions, including tachycardia, hypertension, anxiety, and insomnia. If a regular dose is missed, a double dose should not be taken to compensate, as this may cause an overdose. Patients with severe renal impairment are advised to use the drug with caution, as the elimination of metabolites may be delayed. Any changes in dosage or administration schedule must be agreed upon with a physician who takes into account all individual patient characteristics and concomitant therapy.

How to take ARTVIGIL 150 correctly?

ARTVIGIL 150 is taken orally; the tablet should be swallowed whole with a sufficient amount of water, without chewing or crushing, as this may affect the release rate of the active component. The drug can be taken with or without food, but it should be kept in mind that high-fat food may delay the onset of the therapeutic effect by approximately one hour. To achieve maximum efficacy, it is recommended to take the tablet at the same time every day, which helps maintain a stable concentration of armodafinil in the blood. Night shift workers should take the drug one hour before starting work, rather than in the morning, to avoid disrupting daytime sleep after a shift.

If a dose of ARTVIGIL 150 is missed, it should be taken as soon as possible, provided there are more than 12 hours remaining until the next scheduled dose. If the time for the next dose is close, the missed dose should be skipped and the regular schedule resumed to avoid accumulation of the drug in the body and the development of side effects. It is strictly prohibited to take a double dose to make up for a missed one, as this can lead to overdose with severe cardiovascular and neurological complications. During treatment, it is recommended to avoid alcohol consumption, as ethanol can exacerbate the side effects of the drug and reduce its therapeutic efficacy.

Special attention should be paid to sleep hygiene during ARTVIGIL 150 therapy, as the drug does not replace full night's rest, but only helps maintain wakefulness when needed. Patients are advised to ensure sufficient sleep duration — at least 7–8 hours per day — to avoid chronic fatigue and nervous system exhaustion. If signs of overstimulation appear, such as severe anxiety, tremor, palpitations, or persistent insomnia, it is necessary to consult a doctor to adjust the dose or administration schedule. Treatment with the drug requires regular medical supervision, especially in the first months of therapy, when the body adapts to the action of armodafinil.

Side effects of ARTVIGIL 150

The most common side effects of ARTVIGIL 150 are headache, which usually occurs at the beginning of treatment and gradually diminishes with continued therapy, as well as nausea and dry mouth, related to the drug's effect on the autonomic nervous system. Some patients experience a decrease in appetite, which may lead to slight weight loss during prolonged use, so monitoring nutritional status is recommended. Insomnia and increased anxiety are also possible, especially when taking the drug in the second half of the day or exceeding the recommended dose. These reactions are usually transient and do not require discontinuation of the drug, but their appearance should be reported to a physician.

Less common side effects include tachycardia, increased blood pressure, palpitations, and chest pain, which require immediate medical evaluation, especially in patients with cardiovascular diseases. Nervous system effects may include dizziness, tremors, coordination disorders, and paresthesias, which usually resolve when the dose is reduced. Psychiatric reactions include irritability, emotional lability, depressed mood, and in rare cases, hallucinations or manic episodes, requiring special caution in patients with a history of psychiatric disorders. Allergic reactions such as skin rash, itching, urticaria, and angioedema are rare, but potentially dangerous and require immediate drug discontinuation.

In rare cases, serious skin reactions may develop, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which are life-threatening conditions requiring emergency medical care. Patients should seek immediate medical attention if any rash appears, especially if accompanied by fever, joint pain, or general malaise. Individual responses to the drug can vary significantly, so it is important to carefully observe one's condition during the first weeks of treatment and report any unusual symptoms to a doctor. Regular monitoring of blood pressure and heart rate is recommended for all patients taking ARTVIGIL 150, especially in the presence of cardiovascular risk factors.

Contraindications of ARTVIGIL 150

Absolute contraindications to the use of ARTVIGIL 150 are hypersensitivity to armodafinil, modafinil, or any inactive ingredient of the drug, which may manifest as allergic reactions of varying severity. The drug is not prescribed to patients with severe anxiety, psychomotor agitation, and psychotic disorders, as the stimulating effect can aggravate these conditions. The presence of severe cardiovascular diseases, including uncontrolled hypertension, recent myocardial infarction, unstable angina, and serious arrhythmias, is a contraindication due to the risk of complications. The drug should also not be used in patients with hypertrophic cardiomyopathy and mitral valve prolapse with clinically significant regurgitation.

Relative contraindications requiring special caution and careful weighing of benefits and risks include severe hepatic impairment, where drug metabolism may be significantly delayed. Patients with renal impairment are advised to use the drug with caution, as metabolite excretion may be impaired. A history of psychiatric disorders, including depression, bipolar disorder, and schizophrenia, requires close monitoring during treatment due to potential symptom exacerbation. In patients with a tendency toward substance abuse, the drug is prescribed with caution due to the potential risk of dependency, although it is significantly lower compared to classic stimulants.

The use of ARTVIGIL 150 during pregnancy is not recommended, as there are insufficient data regarding safety for the fetus, and animal studies have shown potential adverse effects on embryo development. Women of childbearing potential are advised to use reliable methods of contraception during treatment, as armodafinil can reduce the effectiveness of hormonal contraceptives. The drug is not used in children and adolescents under 18 years of age due to a lack of sufficient safety and efficacy data in this age group. During breastfeeding, the use of the drug is not recommended, as it is unknown whether armodafinil passes into breast milk, and potential risk to the infant cannot be excluded. In elderly patients, the drug is prescribed with caution due to an increased risk of cardiovascular complications and liver or kidney function impairments.

Interactions of ARTVIGIL 150 with other drugs and alcohol

ARTVIGIL 150 can interact with many medications due to its effect on the cytochrome P450 enzyme system, specifically the CYP3A4 isoenzyme. The drug can reduce the effectiveness of hormonal contraceptives, including oral, transdermal, and implantable forms, so women are advised to use additional or alternative contraceptive methods during treatment and for one month after its completion. Concomitant use with anticoagulants, such as warfarin, requires regular monitoring of blood clotting parameters, as enhancement or weakening of their action is possible. The drug can decrease blood concentrations of cyclosporine, midazolam, and triazolam, requiring adjustment of their doses during co-administration.

The consumption of alcohol during ARTVIGIL 150 treatment is strictly not recommended, as ethanol can intensify central nervous system side effects of the drug, including dizziness, impaired coordination, and reduced concentration. Furthermore, combining a stimulant with alcohol creates an additional burden on the cardiovascular system and liver, increasing the risk of complications. The drug can mask the subjective feeling of intoxication, leading to an inadequate assessment of one's condition and increasing the risk of dangerous behavior. Patients should avoid driving vehicles or operating machinery until individual tolerance to the drug is established, as dizziness and visual disturbances are possible. When used concurrently with other medications affecting the central nervous system, including antidepressants, sedatives, and hypnotics, consultation with a physician is required to assess potential interactions.

Where to buy ARTVIGIL 150 in Ukraine

ARTVIGIL 150 is available for purchase in pharmacy chains across Ukraine upon presentation of a prescription from a doctor, as the drug belongs to the prescription-only category of medications. Before purchasing, it is recommended to check the availability of the drug in a specific pharmacy, as it may not be available at all sales points due to the specificity of the category. The drug can also be ordered through online platforms specializing in pharmaceutical delivery; however, it is necessary to ensure the reliability of the supplier and the presence of appropriate licenses. It is important to store ARTVIGIL 150 in a dry place protected from light at a temperature not exceeding 25 degrees Celsius, out of reach of children, adhering to the expiration date indicated on the package.

When purchasing the drug, attention should be paid to packaging integrity, the presence of protective elements, and compliance of the labeling with the original product from the manufacturer Signature. Self-medication with ARTVIGIL 150 is unacceptable, so consulting a doctor is mandatory prior to purchasing and using the drug to establish an accurate diagnosis and determine the appropriateness of therapy. The doctor will also provide recommendations regarding the optimal dosage regimen, course duration, and possible interactions with other medications taken by the patient. Individual body responses to the drug may vary, so during treatment, it is important to follow specialist recommendations and report any changes in well-being in a timely manner.